Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only: the SIOP 93-01 and 2001 protocols
Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomy...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 January 2022
|
| In: |
European journal of cancer
Year: 2022, Volume: 163, Pages: 88-97 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2021.12.014 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2021.12.014 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804921012855 
|
| Author Notes: | Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1808744187 | ||
| 003 | DE-627 | ||
| 005 | 20240416193731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220701s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2021.12.014 |2 doi | |
| 035 | |a (DE-627)1808744187 | ||
| 035 | |a (DE-599)KXP1808744187 | ||
| 035 | |a (OCoLC)1341461900 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Groenendijk, Alissa |e VerfasserIn |0 (DE-588)1261569717 |0 (DE-627)1808745051 |4 aut | |
| 245 | 1 | 0 | |a Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only |b the SIOP 93-01 and 2001 protocols |c Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis |
| 264 | 1 | |c 15 January 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.07.2022 | ||
| 520 | |a Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. | ||
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a SIOP protocol | |
| 650 | 4 | |a Treatment outcome | |
| 650 | 4 | |a Wilms tumour | |
| 700 | 1 | |a van Tinteren, Harm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jiang, Yilin |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Krijger, Ronald R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vujanic, Gordan M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Godzinski, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rübe, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schenk, Jens-Peter |e VerfasserIn |0 (DE-588)1055855114 |0 (DE-627)792738667 |0 (DE-576)260795577 |4 aut | |
| 700 | 1 | |a Morosi, Carlo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pritchard-Jones, Kathy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Al-Saadi, Reem |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vaidya, Sucheta J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verschuur, Arnauld C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ramírez-Villar, Gema L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Graf, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Camargo, Beatriz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Drost, Jarno |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perotti, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a van den Heuvel-Eibrink, Marry M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brok, Jesper |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spreafico, Filippo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mavinkurve-Groothuis, Annelies M. C. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 163(2022) vom: März, Seite 88-97 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols |
| 773 | 1 | 8 | |g volume:163 |g year:2022 |g month:03 |g pages:88-97 |g extent:10 |a Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2021.12.014 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804921012855 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220701 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1055855114 |a Schenk, Jens-Peter |m 1055855114:Schenk, Jens-Peter |d 910000 |d 911400 |d 50000 |e 910000PS1055855114 |e 911400PS1055855114 |e 50000PS1055855114 |k 0/910000/ |k 1/910000/911400/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1808744187 |e 4159879888 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Alissa","display":"Groenendijk, Alissa","family":"Groenendijk"},{"role":"aut","given":"Harm","display":"van Tinteren, Harm","family":"van Tinteren"},{"role":"aut","given":"Yilin","display":"Jiang, Yilin","family":"Jiang"},{"given":"Ronald R.","role":"aut","family":"de Krijger","display":"de Krijger, Ronald R."},{"given":"Gordan M.","role":"aut","display":"Vujanic, Gordan M.","family":"Vujanic"},{"role":"aut","given":"Jan","family":"Godzinski","display":"Godzinski, Jan"},{"family":"Rübe","display":"Rübe, Christian","role":"aut","given":"Christian"},{"role":"aut","given":"Jens-Peter","display":"Schenk, Jens-Peter","family":"Schenk"},{"given":"Carlo","role":"aut","display":"Morosi, Carlo","family":"Morosi"},{"display":"Pritchard-Jones, Kathy","family":"Pritchard-Jones","role":"aut","given":"Kathy"},{"role":"aut","given":"Reem","display":"Al-Saadi, Reem","family":"Al-Saadi"},{"role":"aut","given":"Sucheta J.","family":"Vaidya","display":"Vaidya, Sucheta J."},{"display":"Verschuur, Arnauld C.","family":"Verschuur","given":"Arnauld C.","role":"aut"},{"family":"Ramírez-Villar","display":"Ramírez-Villar, Gema L.","role":"aut","given":"Gema L."},{"family":"Graf","display":"Graf, Norbert","given":"Norbert","role":"aut"},{"given":"Beatriz","role":"aut","display":"de Camargo, Beatriz","family":"de Camargo"},{"family":"Drost","display":"Drost, Jarno","role":"aut","given":"Jarno"},{"display":"Perotti, Daniela","family":"Perotti","given":"Daniela","role":"aut"},{"given":"Marry M.","role":"aut","display":"van den Heuvel-Eibrink, Marry M.","family":"van den Heuvel-Eibrink"},{"family":"Brok","display":"Brok, Jesper","role":"aut","given":"Jesper"},{"role":"aut","given":"Filippo","display":"Spreafico, Filippo","family":"Spreafico"},{"display":"Mavinkurve-Groothuis, Annelies M. C.","family":"Mavinkurve-Groothuis","given":"Annelies M. C.","role":"aut"}],"language":["eng"],"origin":[{"dateIssuedDisp":"15 January 2022","dateIssuedKey":"2022"}],"note":["Gesehen am 01.07.2022"],"title":[{"title":"Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only","title_sort":"Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only","subtitle":"the SIOP 93-01 and 2001 protocols"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1808744187","relHost":[{"titleAlt":[{"title":"EJC online"}],"part":{"year":"2022","pages":"88-97","text":"163(2022) vom: März, Seite 88-97","extent":"10","volume":"163"},"language":["eng"],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"display":"European School of Oncology","role":"isb"}],"id":{"eki":["266883400"],"zdb":["1468190-0"],"issn":["1879-0852"]},"recId":"266883400","disp":"Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocolsEuropean journal of cancer","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"pubHistory":["28.1992 -"],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-"}],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}]}],"name":{"displayForm":["Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis"]},"physDesc":[{"extent":"10 S."}],"id":{"eki":["1808744187"],"doi":["10.1016/j.ejca.2021.12.014"]}} | ||
| SRT | |a GROENENDIJOUTCOMEOFS1520 | ||